SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

April 1, 2005
Date of Report
(Date of earliest event reported)
 
RITA Medical Systems, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)
 
000-30959
94-3199149
(Commission File Number)
(I.R.S. Employer Identification No.)

967 N. Shoreline Blvd.
Mountain View, CA 94043
(Address of principal executive offices, with zip code)

(650) 314-3400
(Registrant's telephone number, including area code)
 

 
Item 8.01. Other Events and Required FD Disclosure.

On April 1, 2005, RITA Medical Systems, Inc., a Delaware corporation (“RITA”), announced publication of an article in the Journal of Clinical Oncology documenting improved survival rates for colorectal liver metastases patients treated with a combination of radiofrequency ablation and chemotherapy compared to chemotherapy alone. A copy of RITA’s press release detailing the results of the studies is attached as Exhibit 99.1 hereto and incorporated by reference herein.


 
SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  RITA Medical Systems, Inc.
 
 
 
 
 
 
Date: April 1, 2005 By:   /s/ Donald Stewart
 
Donald Stewart, Chief Financial Officer and
Vice President Finance and Administration
  Title 
 


RITA MEDICAL SYSTEMS, INC.

INDEX TO EXHIBITS


Exhibit Number
Description
 
     
99.1
Press Release of RITA Medical Systems, Inc. dated April 1, 2005.